12 results match your criteria: "HealthPlus Network of Specialty Centers[Affiliation]"
Recurrent implantation failure: science or fiction?
Hum Reprod
January 2025
HealthPlus Fertility Center, HealthPlus Network of Specialty Centers, Abu Dhabi, United Arab Emirates.
Add-ons in medically assisted reproduction: from evidence to clinical practice.
Hum Reprod
December 2024
Westmead Fertility Centre, Institute of Reproductive Medicine, University of Sydney, Westmead, NSW, Australia.
Is AMH a promising predictive biomarker for mTESE success in iNOA patients?
Hum Reprod
October 2024
IVF Department, Ar-Razzi Hospital, Ramadi, Iraq.
Agree to disagree: reaching consensus amongst embryologists on the clinical management of low-quality blastocysts.
Hum Reprod
June 2024
EUGIN Group, Barcelona, Spain.
Oxidative stress and ovarian aging: from cellular mechanisms to diagnostics and treatment.
Hum Reprod
July 2024
EUGIN Group, R&D, Barcelona, Spain.
When disaster strikes: risk management and implementing emergency vitrification protocols in IVF laboratory crises.
Hum Reprod
April 2024
Westmead Fertility Centre, Institute of Reproductive Medicine, University of Sydney, Westmead, NSW, Australia.
Chemoprotection of the ovary: a leading role or a complementary strategy in fertility preservation?
Hum Reprod
June 2024
Kinderwunschzentrum, Klinik für Reproduktions-Endokrinologie, Universitätsspital Zürich, Zurich, Switzerland.
Understanding and addressing unexplained infertility: from diagnosis to treatment.
Hum Reprod
May 2024
Independent Researcher, London, UK.
Seroepidemiology of Treponema pallidum, Mycoplasma hominis, and Ureaplasma urealyticum in fertility treatment-seeking patients in the Emirate of Abu Dhabi, United Arab Emirates.
J Infect Public Health
January 2024
Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates; Zayed Center for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. Electronic address:
Article Synopsis
- The study focused on the presence of three genital pathogens (Treponema pallidum, Ureaplasma urealyticum, and Mycoplasma hominis) in patients seeking fertility treatment in Abu Dhabi, highlighting their potential impact on fertility.
- A total of 308 patients were surveyed, revealing that 53% tested positive for at least one pathogen, with Mycoplasma hominis being the most commonly found.
- The findings indicated that lower education levels and unemployment were associated with higher seroprevalence rates, suggesting a need for better awareness and screening of genital pathogens among these populations.
Unpacking the artificial intelligence toolbox for embryo ploidy prediction.
Hum Reprod
December 2023
EUGIN Group, R&D, Barcelona, Spain.
Balancing the scales: the interplay of diet, exercise, GLP-1 receptor agonists, and obesity in shaping male reproductive health.
Hum Reprod
August 2023
Independent Researcher, Maidenhead, UK.
Characterization of Fertility Clinic Attendees in the Abu Dhabi Emirate, United Arab Emirates: A Cross-Sectional Study.
Int J Environ Res Public Health
January 2023
Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 17666, United Arab Emirates.
Article Synopsis
- The study examined primary and secondary infertility in patients from fertility clinics in Abu Dhabi, UAE, focusing on factors linked to primary infertility.
- Out of 928 patients, a significant percentage were overweight or obese, and secondary infertility was found to be more prevalent (62.5%) compared to primary infertility (37.5%).
- Key factors associated with primary infertility included younger age, non-overweight status, marriage duration of ≤5 years, and certain health conditions, while preventable risk factors like obesity and smoking were noted among attendees.